retatrutide trial results news VisualAbstract: reduces body weight by 17.5% in patients with obesity When will Retatrutide be available

72 In a non-randomized cohort study, exenatide-treated subjects with T2D ( n = 71) reported greater well-being and lower Hospital Anxiety and Depression Scale scores compared to matched insulin-treated patients ( n = 67) after 6 months of therapy

Interestingly, the study did not find a lower risk of Parkinsons disease or brain hemorrhages (a type of stroke caused by bleeding)

Hair loss was not a prominently reported adverse event in the phase 2 retatrutide trial

$200 2 month Available only for existing customers purchasing a 2 month GLP-1 refill at check in

Integration of molecular biomarkers with clinical severity scores such as IHS4 may enable precision medicine approaches, optimizing patient stratification and guiding early, targeted intervention